The ocular portion is up ~15% as the eye drug implant shows promise in an ongoing Phase 1 trial

Digital background of wavy eye lines


Ocular Therapeutix (NASDAQ: OKO) reported 10-month interim data from a US phase 1 trial of OTX-TKI, an intravitreal hydrogel implant containing axitinib.

Axitinib is a tyrosine kinase inhibitor being developed to treat wet age-related macular degeneration (wet AMD), diabetic retinopathy and other retinal diseases, according to

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *